 |
Rare Insights: Uncovering The Future Of Rare Disease TreatmentsAuthor: Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Todays Kira Dineen)
On Rare Insights we bridge the gap between those living with rare diseases and the biopharmaceutical industry. Know Rare amplifies the voices of individuals with rare conditions, providing invaluable perspectives to accelerate therapeutic solutions. Join us as we dive deep into the complexities of rare diseases, exploring real-world insights from passionate industry leaders. Together, we navigate the unknowns and unlock the potential for groundbreaking treatments. Because in this journey, were all rare, sharing unique insights and experiences that drive innovation and progress. Our host is Taren Grom, a well-respected media executive, who co-founded and then sold PharmaVoice, the preeminent trade magazine for life science executives at all stages of their careers. PharmaVoice focused on humanizing the people behind the science, a similar sensibility to Know Rare. If you are in the biopharma industry and would like more information about Know Rare, visit knowrare.com/sponsors. Any questions, episode ideas, guest pitches, or comments can be sent into podcast@knowrare.com. For our blog and other podcasts and video content, visit knowrare.com. Be sure to follow us on social media! We are @KnowRare on Instagram, X, and LinkedIn. Please rate and review the podcast on Apple, Spotify, or wherever you listen. This truly helps us climb the charts and allow more bio-pharmaceutical executives and other industry leaders, like yourself, to discover the show. Rare Insights team includes Taren Grom, Liz Kay, Kaitlyn Taylor, DNA Todays Kira Dineen, and Nina Wachsman, CEO and co-founder of Know Rare. We hope you enjoy listening to Rare Insights. Join us to uncover the future of rare disease treatment. Language: en Genres: Chemistry, Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
#4 Conquering the Science of Muscle Disease with Edgewise Therapeutics
Episode 4
Sunday, 29 September, 2024
In this episode of "Rare Insights," host Taren Grom speaks with Dr. Joanne Donovah, Chief Medical Officer at Edgewise Therapeutics, about groundbreaking advancements for severe, rare muscle disorders. Dr. Donovan shares why Edgewise’s approach to targeting the basic unit of muscle contraction and being able to preserve and protect muscle function can have a positive impact on both Becker and Duchene patients. This episode also explores why leaning into understanding the patient voice can benefit drug development overall. Joanne M. Donovan, M.D., Ph.D., has been Chief Medical Officer at Edgewise Therapeutics, a biotechnology company focused on rare muscle disorders, since April 2021. Dr. Donovan has been deeply involved in clinical development for Duchenne muscular dystrophy for the last decade in her role as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals. From 1998 to 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme. Since 1989, she has been a staff physician at the VA Boston Healthcare System and is currently an Associate Clinical Professor of Medicine at Harvard Medical School. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital. Discussion Topics: Introduction to Edgewise Therapeutics: Exploring the company’s foundational experience in small molecule engineering and expertise in muscle biology Understanding Cellular Machinery: Preserving and protecting muscle function can translate to improved outcomes Empowering the Patient Community: By listening to patients’ voices, there is an opportunity to enhance the foundation of drug development Technology Advancement: Incorporating remote access tools can lessen the burden of disease for patients during clinical trials Living the Legacy in Rare Disease: Dr. Donovan’s experience while at Genzyme has shaped her approach to understanding and overcoming the barriers associated with rare diseases Thank you to Dr. Joanne Donovan, for taking the time to discuss the company’s innovative approach to targeting the “muscle as an organ” in its pursuit of treatments for rare neuromuscular and cardiac diseases, including Becker and Duchene muscular dystrophy. Stay tuned for the next new episode of Rare Insights! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “Rare Insights”. Rare Insights’ team includes Taren Grom, Liz Kay, Kaitlyn Wosik, DNA Today’s Kira Dineen, and myself, Nina Wachsman. See what else we are up to on X, Instagram, Facebook, YouTube, and our website, knowrare.com. Questions/inquiries can be sent to podcast@knowrare.com.
